2001 Drug Development Pharmaceutical Companies 
European Pharmaceutical Review
JULY 4, 2024
4,6 Five patent issues that European biosimilar developers should consider before entering the US market Quality control of the botanical drug substances was one of the critical factors that led to barricades during the development of Veregen and Mytesi. 13 Currently, over 350 herbal remedies have been granted a THR licence.
Pharmaceutical Technology
JUNE 29, 2022
Almost 40 years since it was instituted, some have described the FDA’s orphan drug program, which is meant to foster innovation, as “ one of the most successful US legislative actions in recent history ”. During 2001–10, the number of granted designations almost tripled, with 1,527 drugs receiving their first orphan drug designation.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JUNE 8, 2021
“But we are glad to see the situation for innovative drugs in Asian markets improving, especially in mainland China and South Korea, where policies, societies and regulations are actively promoting innovation. “At At the same time, lots of people with experience at multinational pharmaceutical companies have chosen to return home.
pharmaphorum
SEPTEMBER 18, 2020
But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharma companies in the world: AstraZeneca.
PharmaShots
FEBRUARY 20, 2023
After the outbreak of any epidemic or pandemic, all the responsibilities come on the shoulders of pharmaceutical companies. With unprecedented diseases lurking on the corner, pharmaceutical companies, are now obligated to widen their conventional horizons and look for substitute practices in their drug development strategies.
PharmaShots
FEBRUARY 21, 2023
Market Cap: $29.30M Founded Year: 2001 Total Employees: ~20 Headquarters: Tokyo, Japan Stock Exchange: TYO Perseus Proteomics is a Japanese biotech company focused on developing antibodies by utilizing antibody technology to provide treatment options to patients worldwide.
Pharmaceutical Technology
FEBRUARY 28, 2023
For many years, the pharmaceutical industry has been accused of overlooking this patient population by instead targeting investments toward more prevalent indications. Orphan drug development is expanding Change is happening. With similar incentives offered by EU/EEA and UK law, orphan drug development has taken off.
Expert insights. Personalized for you.
103 
Let's personalize your content